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Abstract
A phase 1 clinical trial in healthy male volunteers was conducted with a somatostatin-dopamine chimera (BIM23B065),
from which information could be obtained on the concentration-effect relationship of the inhibition of pulsatile endogenous
growth hormone and prolactin secretion. Endogenous growth hormone profiles were analyzed using a two-step decon-
volution-analysis-informed population pharmacodynamic modeling approach, which was developed for the analyses of
pulsatile profiles. Prolactin concentrations were modelled using a population pool model with a circadian component on the
prolactin release. During treatment with BIM23B065, growth hormone secretion was significantly reduced (maximal effect
[EMAX] = - 64.8%) with significant reductions in the pulse frequency in two out of three multiple ascending dose cohorts.
A circadian component in prolactin secretion was identified, modelled using a combination of two cosine functions with
24 h and 12 h periods. Dosing of BIM23B065 strongly inhibited (EMAX = - 91%) the prolactin release and demonstrated
further reduction of prolactin secretion after multiple days of dosing. This study quantified the concentration-effect
relationship of BIM23B065 on the release of two pituitary hormones, providing proof of pharmacology of the chimeric
actions of BIM23B065.
Keywords Growth hormone  Deconvolution  Prolactin  Population PKPD  Dopastatin
Introduction
The pituitary is a key endocrine gland that produces a wide
variety of hormones, including growth hormone (GH) and
prolactin (PRL) [1]. In acromegaly, a pituitary adenoma
causes disruption in the highly regulated mechanisms that
control the stimulation and inhibition of GH [2]. Pituitary
adenomas cause severe GH hypersecretion [3, 4] and may
also lead to an excessive release of PRL in 20–30% of
patients [2, 4].
Recently, a placebo-controlled single ascending and
multiple ascending dose phase I clinical trial was per-
formed to study the pharmacokinetics (PK), safety and
tolerability of BIM23B065 in healthy male volunteers [5].
BIM230B065 belongs to the novel class of dopastatins,
which concurrently target somatostatin and dopamine
receptors and is under investigation for the treatment of
neuro-endocrine tumors [6]. The effects of BIM23B065 on
endogenous GH and PRL secretion has previously been
reported on a per-cohort basis. However, no concentration-
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effect relationship between BIM23B065 and GH and PRL
secretion has yet been established.
To quantify the pharmacokinetic/pharmacodynamic
(PK/PD) relationship on endogenous GH secretion, com-
monly the mean of multiple GH observations [7, 8], the
area under the GH-concentration–time curve [9], or a
simplification of the circadian rhythm of GH was used [10].
However, these methods do not incorporate the high intra-
and inter-individual variability in pulsatility that is char-
acteristic of endogenous GH profiles. Therefore, these are
at best an empirical way to quantify a drug effect and have
limited utility for the prediction of drug effects with new
dosing regimens. For PRL response modelling, different
structural PD models with different levels of complexity
(turnover model, pool model, agonist–antagonist interac-
tion and combinations of a pool model with a feedback
loop [11–14]) are reported in the literature with some
including circadian rhythmicity modelled as two cosine
functions with 12 h and 24 h periods [11, 13].
The aim of this study was to quantify the PK/PD rela-
tionship between BIM23B065 plasma concentrations and
the endogenous GH secretion, while taking into account an
individual’s pulsatile profile, and of the PRL secretion,




A phase 1, double-blind, randomized, placebo-controlled
single (S.A.D.) and a 13-day multiple ascending dose
(M.A.D.) clinical trial was performed to primarily inves-
tigate the PK, safety, and tolerability of subcutaneously
administered BIM23B065 [5]. In short, a total of 64 heal-
thy male volunteers were included in the study, of which
one individual withdrew from the study before dose
administration and was not replaced. Cohorts consisted of 8
individuals (active n = 6, placebo n = 2 per cohort) and
received doses of 0.1 mg, 0.4 mg, 0.8 mg, 1.2 mg or
1.5 mg in the S.A.D. cohorts or 1.2 mg once daily (q.d.),
0.8 mg twice daily (b.i.d.) and 1.0 mg b.i.d. in the M.A.D.
cohorts, administered at 8 h/16 h intervals.
Endogenous GH and PRL sampling was performed once
during the S.A.D. and twice, on day 7 and day 12, during
the M.A.D. part of the study. Sampling started 2 h before
dose administration in the S.A.D. part and 1 h before
dosing in the M.A.D part of the study. Sampling was
performed up until 12 h after dosing in the S.A.D part and
11 h after dosing in the M.A.D. part at 20 min intervals,
except in the first hour after dosing of the S.A.D. cohorts,
where it followed the PK sampling schedule (15, 30,
60 min after dosing). The GH samples were analyzed using
the Immulite 2000 assay (WHO IS 98/572) and the PRL
samples using a two-step immunoassay (Architect Pro-
lactin assay).
GH model development
All individual GH profiles were analyzed with a decon-
volution analysis in which the baseline secretion, the
elimination rate, and the pulsatile secretion events were
extracted from an individual profile. The pulsatile secretion
events were assumed to follow a Gaussian shape and the
optimal number, the location of secretion events, and the
Gaussian pulse width of an individual were determined.
This methodology has been shown to have high sensitivity
and specificity in the identification of pulses in endogenous
pulsatile hormonal profiles [15].
The individual deconvolution analysis of GH profiles
was performed in AutoDecon (developed by Johnson et al.)
which requires regularly spaced observations, an initial
pulse secretion, and an initial half-life as input [15].
Therefore, a data transformation was performed to main-
tain the required regularly spaced 20 min sampling inter-
val. As such, the time points at 15 and 30 min after dosing
in the S.A.D. cohorts were shifted by 5 and 10 min
respectively to maintain a 20-min interval throughout the
full observation period. The initial pulse secretion width
was set to half of the sampling interval (10 min) and the
initial GH half-life was set to 15 min. The pulse frequency,
obtained from the deconvolution analysis, of BIM23B065
treated individuals was analyzed for significance (gener-
alized linear model with Poisson distribution, p\ 0.05)
compared with the placebo cohort. The pulse frequency
and the location of pulses from the deconvolution analysis
were converted to a format suitable for population NLME
modelling in NONMEM [16, 17].
The deconvolution-informed PD modeling of endoge-
nous GH profiles followed a sequential modelling proce-
dure. First, modelling started with the estimation of the
population parameters in placebo treated individuals. Inter-
individual variability (IIV) in the population parameters
and between-occasion variability (BOV) between day 7
and day 12 was included following a bottom-up inclusion
procedure. Then, the estimated population parameters and
variance distributions were fixed to the placebo estimates
and model development continued with the full dataset
containing both placebo and BIM23B065 treated individ-
uals [17]. Multiple PK/PD relationships, linear and (sig-
moidal) maximal effect (EMAX), driven by the plasma PK
of BIM23B065 or via an effect compartment, were tested
for significance on the baseline secretion and pulse
amplitude parameters during model development [18]. The
EMAX relationship in which the hill coefficient (c) was
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estimated or fixed to 1, and where the EMAX parameter was
estimated or fixed to - 100% on the pulse amplitude (as-
suming a full inhibition of GH secretion) was explored.
PRL model development
The data from this study did not include any information on
the concentrations of inhibitory feedback hormones for
PRL. Furthermore, no dose administrations with short
consecutive dosing intervals were administered, which
complicated the estimation of feedback mechanisms on
PRL secretion and therefore model development focused
on the quantification of a pool model, as proposed by
Movin-Osswald et al. [14]. As a circadian component in
the release of PRL secretion was expected [19], all time
points in the dataset were normalized to 6 a.m. and the
model included a 24 h initialization period. The periodicity
of the circadian rhythm of PRL secretion was explored by
implementing a cosine function (Eq. 1) in the structural
model while only including data from the placebo treated
individuals.
DIU ¼ HAmplitude  cosð2p  t HPhaseshift
period
Þ ð1Þ
where DIU is the diurnal effect over time (t), HAmplitude is
the height of the peak (or trough) of the cosine function
from the mesor, HPhaseshift is the horizontal shift in the
cosine and period is the time needed to complete a single
cycle. Multiple periods, and combinations of 2 cosine
functions, were investigated to account for the circadian
rhythm observed in the data. Periods were chosen so that
all cycles were completed in a 24 h period. The circadian
rhythm was implemented on the PRL release rate constant
(kr) from the pool compartment. The PRL-inhibiting effect
of BIM23B065 was investigated by the use of linear or
sigmoidal EMAX PK/PD relationships on the kr.
Inter-individual variability, between-occasion
variability and covariates
In both models, the IIV and BOV were included following
a bottom-up inclusion procedure. Both IIV (g) and BOV
(,) were assumed to follow a log-normal distribution (ex-
cept phase shift parameters) and were included when a
significant improvement (p\ 0.01) in model fit was
observed and the numerical stability of the model was
improved. The covariates age, weight, body mass index,
height and lean body mass were investigated as descriptors
of the identified IIV. Correlations between the post hoc
Bayesian estimates and the covariates were evaluated and
tested for inclusion in the structural model when a corre-
lation (r2[ 0.50) was present. Covariates were centered
around their mean values upon inclusion in the model.
Covariates were included using a forward inclusion method
(p\ 0.05) followed by backward deletion (p\ 0.01).
Model evaluation
Model selection and evaluation was based on a significant
(p\ 0.01) drop in the objective function value (OFV) of
6.64 points between nested models after the addition of one
degree of freedom, goodness of fit (GOF) plots and addi-
tional numerical evaluation with a focus on the relative
standard errors (RSE) of population parameters and the g-
shrinkage. In general, RSEs of population parameters were
considered acceptable when below 50% and g-shrinkage
should not exceed 30% [20]. When the covariance step in
NONMEM was not completed, RSEs were computed from
successfully minimized models in a non-parametric boot-
strap of 50 samples.
Models were visually judged for bias on the basis of GOF
figures, which included the individual (IPRED) and popu-
lation (PRED) model predictions versus observations and
conditional weighted residuals with interaction (CWRESI)
versus PRED and time after dose [20]. The IPRED and
PRED versus observations should show a scatter around the
line of unity whereas the CWRESI over PRED and time after
dose should show a homogenous scatter around 0 with the
majority of data points between the [- 2, 2] interval. When
cosine functions were included in a model to account for
circadian variability, CWRESI over time of day was
explored to identify a circadian bias. When computational
power constraints and model run times were accept-
able (\ 2 days), a non-parametric bootstrap analysis was
performed, using 1000 samples, as interval validation for the
calculation of the median and the 95% confidence intervals
of the parameter estimates. For the PRL model, a prediction
corrected visual predictive check (pcVPC) was created over
clock time. No pcVPC could be created for the GHmodel as
model diagnostic due to the differences in the timing of
pulses. Therefore, normalized prediction distribution errors
(NPDE) were computed for all models, stratified per treat-
ment day, to evaluate model predictions.
Software
Data transformation and graphical analysis was performed
in R (V3.4.0) [21]. Deconvolution analysis was performed
using AutoDecon (V20090124) [15]. NLME modeling was
performed in NONMEM V7.3 [16] in conjunction with
Perl-speaks-NONMEM V4.6.0 [22]. All models were
estimated with the first-order conditional estimation with
interaction (FOCEI) method applying user-written ordinary
differential equations in ADVAN 9 or 13. The non-para-
metric bootstrap was performed using the ‘bootstrap’
command in Perl-speaks-NONMEM.
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Results
A population PK analysis on BIM23B065 has previously
been performed [23]. In short, the PK of BIM23B065 was
best described by a 2-compartment model with both linear
and non-linear elimination kinetics. The individual post-
hoc Bayesian estimates of the previously published PK
model were used to simulate the individual concentration–
time profiles of BIM23B065 for the PK/PD analysis.
GH model development
For endogenousGHprofiles, several individuals did not have
any observations above the lower limit of quantification
(LLOQ) of 0.05 ng/mL during the observation period (1
placebo, 3 BIM23B065 treated). These individuals were
therefore excluded from further analysis. A total of 77 12 h
profiles from 59 individuals consisting of 3054 GH obser-
vations (776 from placebo and 2278 from BIM23B065
treated individuals) were used for model development.
Within the placebo group, 20% of the observations were
below the LLOQ. Within the treated group, this percentage
increased to 43%. The observations below the LLOQ were
fixed to the LLOQ of 0.05 ng/mL in this analysis to maintain
the estimation of basal GH secretion. Figure 1 shows the
concentration–time profiles of multiple representative pla-
cebo- and 1.5 mg BIM23B065-treated individuals, visual-
izing the high level of variability between individuals and
between the pulses within an individual.
The median pulse interval, estimated in the deconvolu-
tion analysis, in the placebo cohort was 74 min (IQR 25%-
75% = 44–160 min, 95% upper boundary = 293 min). The
pulse frequency showed a small but significant reduction in
the 1.2 mg q.d. (p = 0.013) and the 0.8 mg b.i.d. (p = 0.05)
cohorts compared with placebo (Online Resource 1). In
general, a wide range of pulse frequencies was estimated
by the deconvolution analysis in the individual GH profiles
after either placebo or BIM23B065 treatment.
Due to the high number of observations below the
LLOQ, the large interval between two pulses could be the
result of GH inhibition by BIM23B065. However, since
these inhibited pulses cannot be identified in a deconvo-
lution analysis, this would result in missing information on
the concentration-effect curve. Hence, no observations at
the maximum effect (a fully inhibited pulse) are available.
If the pulse interval between two identified pulses was
higher than 300 min, a[ 95% probability of an unidenti-
fied pulse was expected. Therefore, an additional pulse
location in the middle of these two identified pulses was
added to account for this. This was done for both placebo
and treated individuals to prevent a selection bias. As a
result, a total of 34 new pulse locations were included (4
placebo-, 30 BIM23B065-treated pulses) in the dataset.
In the placebo model, significant IIV was estimated on
the elimination rate constant (DOFV = - 264.8), the pulse
secretion width (DOFV = - 162.4), and the GH baseline
secretion (DOFV = - 125.1). The inclusion of BOV was
significant on the elimination rate constant (DOFV =
- 102.4, coefficient of variation [CV] = 8.8%) and the
pulse secretion width (DOFV = - 43.4, CV = 33.2%). A
proportional residual error structure was superior over an
additive or a combined residual error structure.
Placebo parameters were estimated with low RSEs
(\ 10%) with high levels of inter-pulse variability in the
pulse amplitude (CV = 555%). No structural bias could be
identified in the CWRESI versus time which showed the
majority of the points between the [- 2, 2] interval, the
population model predictions showed a broad scatter at the
lowest regions, indicating a wide distribution in the model
fit at the baseline levels (Fig. 2). The individual model
predictions were close to the line of unity, indicating an
adequate model fit for placebo-treated individuals.
Fig. 1 Individual concentration–time growth hormone profiles of
representative placebo treated subjects (a) and BIM23B065 treated
subjects in the 1.5 mg cohort (b). Dashed vertical line at 0 h
represents time of dose administration. Data below the lower limit of
quantification was fixed to 0.05 ng/mL
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After including the data from BIM23B065-treated
individuals, the inclusion of an EMAX concentration-effect
relationship of BIM23B065 on the pulse secretion, origi-
nating from an effect compartment, gave the largest drop in
OFV (DOFV = - 55.4) relative to an absence of drug
effect and was superior to a linear effect (DOFV compared
to no effect = - 38.1). The EMAX was estimated as a
64.8% inhibition of the secretion of GH with an EC50 of
0.609 lg/L. The estimation of a hill coefficient did not
improve the model fit and was therefore fixed to 1. The
inclusion of an additional effect that reduced the basal
secretion of GH was not superior to the parent model. A
drug effect on the basal secretion of GH might be identified
when a more sensitive analysis assay is applied.
The inclusion of IIV on the EC50 resulted in a small, but
significant, decrease in the OFV of 8 points, but with a very
high variance (x2 = 12.1). This indicates the existence of
high variability in the EC50 within this population with
only limited improvement in the individual model fit.
Furthermore, a decrease in numerical stability was
observed in this model after inclusion of the variance on
the EC50, and was therefore excluded from the model. No
significant covariates were identified for inclusion.
The estimated model parameters for the system specific
parameters of GH and the concentration–effect relationship
of BIM23B065 on endogenous GH secretion are shown in
Table 1. The GOF plots of the developed model for pla-
cebo- and active-treated individuals are depicted in Fig. 2.
The individual model predictions are scattered close to the
line of unity. A larger distribution of the CWRESI at the
lowest population predictions was observed, with no bias in
the CWRESI over time since first dose during the three
observation days, with the majority of the model predic-
tions within the [- 2, 2] interval. The condition number
was moderate with a value of 54.4. The structural model
for endogenous GH secretion is depicted in Fig. 3a. Due to
computational power restrictions, no non-parametric
bootstrap was performed. The NPDE results are depicted in
Online Resource 2, showing a normal distribution of the
observations in the Q-Q plot, with a small underestimation
of the median.
Fig. 2 Goodness of fit plots of the developed endogenous growth
hormone model. a Conditional weighted residual with interaction
(CWRESI) versus time since first dose for day 1, 7 and 12.
b Individual model predictions versus GH observations. c CWRESI
versus population growth hormone predictions. Orange dots = pla-
cebo observations, blue squares = BIM23B065 treated observations,
black diagonal line = line of unity, grey dashed line = [- 2, 2]
interval (Color figure online)
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PRL model development
A total of 3116 PRL observations were available for model
development, of which 796 were PRL concentrations of
placebo treated individuals, used for the structural model
development with circadian rhythm, and 2320 PRL con-
centrations were available from BIM23B065-treated indi-
viduals. No samples were below the LLOQ.
Visual inspection of the placebo data indicated a circa-
dian rhythm in the release of PRL, with the time period
during which concentrations were low (bathyphase) in the
morning and higher PRL concentrations during the after-
noon (Online Resource 3). This was best described using a
combination of two cosine functions with 24 h and 12 h
periods on the kr from the pool compartment, giving a 266
point reduction in the OFV compared to a steady state
release, and was superior over other cosine period
combinations.
The inclusion of an inhibitory EMAX drug effect on the
kr, driven by the PK of BIM23B065 gave a 1518 point
reduction in the OFV. An EMAX concentration-effect
relationship was superior over a linear effect (DOFV =
- 938 compared to no drug effect) and over a sigmoidal
EMAX relationship of which the hill factor could not be
accurately estimated.
Graphical model evaluation suggested an overprediction
for individuals in the b.i.d. cohorts of the M.A.D. part of
the study, indicating that the typical PRL concentrations
were reduced after 7 or 12 days of treatment with
BIM23B065 (Online Resource 4A). To investigate whether
prolonged dosing of BIM23B065 would decrease the syn-
thesis of PRL in the pool compartment (ks-PRL), it was
investigated if, and to what extent, significant differences
between day 1 (S.A.D.), day 7 and day 12 (M.A.D.) exis-
ted, driven by the cumulative exposure (mg*h/L) over time
to BIM23B065 using Eq. 2.
IðtÞ ¼ BIM23B065exposure tð Þ HSlope
1þ BIM23B065exposure tð Þ HSlope ð2Þ
Table 1 Model parameter estimates for the population pharmacody-
namic model of the endogenous growth hormone secretion
Parameter Units Estimate [RSE%] (CV%)
Structural model parametersa
Baseline ng/mL 0.056 [0.4]
Secretion width h 0.184 [1.16]
Amplitude ng/mL 1.69 [1.6]
kel-GH /h 3.6 [1.38]
Drug effect parameters
Effect compartment rate /h 1.25 [4.97]
EMAX % - 64.8 [2.7]
EC50 lg/L 0.609 [41.7]
c – 1b
Inter-individual variability
x2 baseline – 0.0288 (17.1)
x2 secretion width – 0.0434 (21)
x2 kel-GH – 0.225 (50.2)
x2 amplituden – 3.46 (555)
x2 BOV secretion width – 0.104 (33.2)
x2 BOV kel-GH – 0.00775 (8.82)
Residual error structure
r2 proportional error – 0.0247
RSE relative standard error, CV% coefficient of variation, 95% CI
95% confidence interval, Amplituden variability between n pulses
within an individual
aStructural model parameters were estimated on placebo data only
bIndicate fixed parameter
Fig. 3 Structural population models for the endogenous GH secretion
(a), the pharmacokinetics of BIM23B065 (b) and the endogenous
prolactin secretion (c). Inhibitory dotted lines indicate inhibition via
EMAX equations. Clock indicates parameter with circadian rhythm.
kbase = baseline secretion, kel-x = elimination rate constant, ke0 = ef-
fect compartment rate, ks-PRL = prolactin synthesis rate, kr = release
rate
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In which the HSlope parameter determines the steepness
of the inhibition curve and the I(t) remains between 0 (no
inhibition) and 1 (full inhibition). The inclusion of a
decrease in ks-PRL over time, driven by the exposure to
BIM23B065, resulted in a 66 point reduction in the OFV,
with a HSlope of 2.73. This improved the population model
fit to a more homogenous scatter around the line of unity
(Online Resource 4B).
Significant IIV was identified on the, in order of inclu-
sion, ks-PRL (DOFV = - 2009), and on the HAmplitude of the
12 h (DOFV = - 365) and 24 h (DOFV = - 298) cosine
functions. A proportional residual error structure was best
fit for purpose. No significant covariates were identified.
The estimated model parameters for the developed PRL
model are shown in Table 2. The structural model for
endogenous PRL secretion is depicted in Fig. 3c. The GOF
plots of the developed model for placebo- and
BIM23B065-treated individuals are depicted in Fig. 4. A
clear difference between the placebo and treated individ-
uals can be observed, in which the PRL concentrations of
placebo individuals are consistently higher. A scatter
around the line of unity for the population and individual
model predictions indicates adequate model fit with large
variability in the population. The condition number was
low with a value of 15.7.
The CWRESI versus time of day shows a minimal bias
around 0, indicating that there is still remaining variability
present that could not be quantified in the current model
solely with the use of two cosine functions. The collection
of additional data may result in the identification of another
cosine function with a shorter period to account for this. No
bias in the CWRESI versus the population predictions was
identified, with the majority of the predictions within the
[- 2, 2] interval. The highest CWRESI of 15.4 was the
result of a high PRL pulse (concentrations up to 39.7 ng/
mL) occurring between the two doses in the M.A.D. part of
the study, where a PRL concentration of 13.3 ng/mL was
estimated. This was also the case, but to a lesser extent,
with other model predictions that had high CWRESI val-
ues. All RSE’s and g-shrinkage were below their accep-
tance criteria of 50% and 30%, indicating precise
estimation of these parameters. Bootstrap medians and
confidence intervals were close to the estimated values.
The NPDE and pcVPC results are depicted in Online
resource 5, showing normal distributions of the distribution
errors on all days and accurate description of the typical
individual and the variability of the population over clock
time. The NONMEM model codes for the GH and PRL
models are available in Online Resource 6.
A simulated effect of BIM23B065 on a typical
endogenous PRL and GH profile over time, at multiple
dosing levels of BIM23B065, is depicted in Fig. 5. A large
reduction in the secretion of both pituitary hormones can be
observed compared with the typical placebo profile.
Table 2 Model parameter estimates for the population pharmacodynamic model of the prolactin secretion
Parameter Units Estimate [RSE%] (CV%) Shrinkage (%) Bootstrap median (95% CI)
Population parameters
kr /h 0.011 [30.2] – 0.011 (0.0009 to 0.260)
kel-PRL /h 1.25 [9.55] – 1.28 (1.03 to 1.63)
ks-PRL ng/mL/h 13.3 [8.54] – 13.6 (10.2 to 17.6)
Amplitude cos 24 h – 0.168 [13.9] – 0.177 (0.08 to 0.28)
Phase shift cos 24 h h 17.3 [3.51] – 17.1 (14.58 to 19.61)
Amplitude cos 12 h – 0.095 [10.8] – 0.088 (0.036 to 0.140)
Phase shift cos 12 h h 10.2 [5.15] – 10.3 (7.50 to 11.44)
EMAX % -91 [5.53] – - 91 (- 78.5 to - 99.65)
EC50 lg/L 1.27 [14.3] – 1.18 (0.77 to 1.85)
Slope – 2.73 [26.9] – 2.36 (0.475 to 10.67)
Inter-individual variability
x2 ks-PRL – 0.068 (26.4) \ 0.01 0.066 (0.046 to 0.091)
x2 amplitude 24 h – 0.57 (87.3) 11.08 0.55 (0.19 to 1.98)
x2 amplitude 12 h – 0.87 (118) 16.96 1.06 (0.47 to 3.83)
Residual error structure
r2 proportional error – 0.049 2.21 0.048 (0.039 to 0.060)
Bootstrap results: 99.4% successful minimizations, 68.0% successful covariance steps runs
RSE relative standard error, CV% coefficient of variation, 95% CI 95% confidence interval
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Discussion
BIM23B065 was able to significantly inhibit the endoge-
nous secretion of GH and PRL by 64.8% and 91%,
respectively. The quantified GH lowering properties of
BIM23B065 show similarities with the in vitro established
inhibition of 63% in cultured human pituitary adenoma
cells [24]. An effect compartment was included to account
for a delay in the effect on the pulsatile GH profile. No
strong reduction in GH pulse frequency was identified,
with only small reductions observed in two out of three
M.A.D. cohorts. For PRL, a strong and direct reduction
was observed after both single and twice-daily BIM23B065
administrations, which lasted for approximately 8 h before
returning back to baseline. The developed PK/PD models
were able to accurately quantify the concentration-effect
relationship after single and multiple doses of BIM23B065
on the endogenous secretion of GH and PRL in healthy
male individuals.
In order to account for the underestimation of the ‘true’
number of pulses in the deconvolution analysis, a pulse
location was added if an interval was larger than the 95%-
percentile of the placebo data. The implementation of these
pulses in the dataset informed the concentration-effect
curve at the section of the maximal effect (informing on the
parameter estimate of EMAX) and enabled the quantification
of the inhibitory BIM23B065 effects with high accuracy in
the parameter estimates. However, the high proportion of
data below the LLOQ limited the precise estimation of the
actual baseline GH secretion in the BIM23B065-treated
individuals. The clear increase in the percentage of data
below the LLOQ in the BIM23B065-treated versus
Fig. 4 Goodness of fit plots of the developed endogenous prolactin
model. a Population model predictions versus observations, b indi-
vidual model predictions versus observations, c conditional weighted
residuals with interaction (CWRESI) versus population predictions,
and d CWRESI versus time of day. Orange dots = placebo observa-
tions, blue squares = BIM23B065 treated observations, black diago-
nal line = line of unity, grey dashed line = [- 2, 2] interval (Color
figure online)
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placebo-treated individuals indicate that BIM23B065 may
have had an effect on this baseline secretion, which could
not be quantified in the current PK/PD model. Furthermore,
the population baseline parameter may be overestimated
and the variance on this baseline parameter may be
underestimated by this approach, which should be taken
into account in subsequent simulations. Due to the high
level of variability, in future studies, a pre-treatment
baseline day could be incorporated in the study design to
better describe the endogenous hormonal secretion of an
individual before administration of BIM23B065.
For PRL, the identified circadian rhythm on the release
rate (two cosine functions with 24 h and 12 h periods) was
similar to the pattern identified by others [13]. As there are
no observations of feedback hormones in this study, which
are applied in different PRL models in literature, a parsi-
monious structural model that was able to adequately
describe the data, with high accuracy in the parameter
estimates (RSE\ 50%) was applied. A pool model to
capture the endogenous PRL release in this study was best
fit for purpose and quantified the significant inhibitory
effects after both single- and multiple-doses of
BIM23B065.
To the best of our knowledge, this is the first time that
the concentration-effect relationship of a drug targeting
endogenous pulsatile GH secretion has been analyzed
Fig. 5 Simulations of a typical PK/PD response after receiving
placebo, 0.4, 0.8, or 1.5 mg single dose at time 0 h, or 1.0 mg with
8 h intervals (q8). a pharmacokinetics of BIM23B065, b typical
response profile on the PRL secretion, c typical response profile on
the GH secretion. Prolactin (PRL) simulation was performed with
dosing at 8 am and 4 pm. Growth hormone (GH) secretion was
simulated with the typical pulse amplitude and pulse frequency,
without variability between pulses
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while maintaining an individual’s pulsatile profile. This
analysis method increased the amount of information that
was obtained from a phase I clinical trial by the quantifi-
cation of a concentration-effect relationship over time
compared with a dose–response relationship based solely
on summary statistics (e.g. mean, area under the curve).
The identified concentration-effect relationships on both
pituitary hormones (GH and PRL) provide information on
the extent of the inhibitory effects of BIM23B065 and
shows that BIM23B065 is able to reduce GH and PRL
secretion in healthy male volunteers, indicative of both
active somatostatin and dopamine moieties. Using the
developed population models for GH and PRL, clinical
trial simulations can be performed to identify the proba-
bility of success of new clinical trial study designs with
BIM23B065. Additionally, the estimated parameters can
be used as prior information in the study design of new
compounds when investigating GH or PRL inhibition.
Especially with the identified GH model, the effect of
different simplified sampling protocols (e.g. 1 random GH
sample, multiple GH sample every 10 min for 1 h, etc.) can
now be simulated and can be taken into consideration in the
design of new trials.
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